Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That Has Relapsed After Standard Induction Therapy

Trial Profile

Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That Has Relapsed After Standard Induction Therapy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Annamycin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Moleculin Biotech
  • Most Recent Events

    • 02 Jul 2020 According to a Moleculin Biotech media release, the European trial is in the best position to complete the safety portion with 5 clinical sites open in Poland.
    • 02 Jul 2020 According to a Moleculin Biotech media release, based on prior clinical trials, dose level may need to increase from 300 to 360 mg/m2, or possibly higher.
    • 02 Jul 2020 According to a Moleculin Biotech media release, first patient treated at 240 mg/m2 with no evidence of cardiotoxicity or other dose limiting toxicities and once 2 more patients are successfully treated at this level, the next cohort will be treated with 300 mg/m2. The dosing will increase in 2020, allowing a recommended Phase 2 Dose to be established in 2021.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top